Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

OBJECTIVE: To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg. DESIGN AND METHODS: Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥6 months and had n...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Endocrinol
Glavni autori: Neggers, Sebastian JCMM, Pronin, Vyacheslav, Balcere, Inga, Lee, Moon-Kyu, Rozhinskaya, Liudmila, Bronstein, Marcello D, Gadelha, Mônica R, Maisonobe, Pascal, Sert, Caroline, van der Lely, Aart Jan
Format: Artigo
Jezik:Inglês
Izdano: Bioscientifica Ltd 2015
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4544680/
https://ncbi.nlm.nih.gov/pubmed/26047625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-15-0215
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items